HK1112753A1 - Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy - Google Patents

Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy

Info

Publication number
HK1112753A1
HK1112753A1 HK08107845.4A HK08107845A HK1112753A1 HK 1112753 A1 HK1112753 A1 HK 1112753A1 HK 08107845 A HK08107845 A HK 08107845A HK 1112753 A1 HK1112753 A1 HK 1112753A1
Authority
HK
Hong Kong
Prior art keywords
application
control
promoter active
cancer therapy
strain expressing
Prior art date
Application number
HK08107845.4A
Other languages
English (en)
Inventor
Gilles Marchal
Mohammad Abolhassani
Original Assignee
Pasteur Institut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut filed Critical Pasteur Institut
Publication of HK1112753A1 publication Critical patent/HK1112753A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
HK08107845.4A 2006-07-25 2008-07-16 Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy HK1112753A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06291205A EP1882741B1 (fr) 2006-07-25 2006-07-25 Souche de Mycobacterium exprimant une proteine FAP sous le contrôle d'un promoteur qui est actif en conditions d' hypoxie et ses applications pour la thérapie du cancer

Publications (1)

Publication Number Publication Date
HK1112753A1 true HK1112753A1 (en) 2008-09-12

Family

ID=37026080

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08107845.4A HK1112753A1 (en) 2006-07-25 2008-07-16 Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy

Country Status (10)

Country Link
US (2) US20090304637A1 (fr)
EP (2) EP1882741B1 (fr)
JP (1) JP2009544305A (fr)
AT (2) ATE472602T1 (fr)
CA (1) CA2658713A1 (fr)
DE (2) DE602006015180D1 (fr)
DK (1) DK1882741T3 (fr)
ES (1) ES2347812T3 (fr)
HK (1) HK1112753A1 (fr)
WO (1) WO2008012693A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140598A2 (fr) * 2006-12-04 2008-11-20 Bacilligen, Inc. Nouvelles microbactéries immunothérapeutiques, formulations pharmaceutiques et utilisation de celle-ci
EP2620159A1 (fr) 2012-01-24 2013-07-31 Institut Pasteur Traitement du cancer amélioré par immunothérapie par BCG ou des mycobactéries non pathogènes apparentées du point de vue des antigènes
AU2013299643A1 (en) * 2012-08-10 2015-03-26 Memorial Sloan-Kettering Cancer Center Predicting bladder cancer responsiveness to BCG
US10494665B2 (en) * 2014-08-20 2019-12-03 Huawei Yang Test kit and method for testing target nucleic acid in sample
CN110291401B (zh) 2016-12-14 2023-04-11 普渡研究基金会 成纤维细胞活化蛋白(fap)-靶向成像和治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6599510B1 (en) * 1993-11-23 2003-07-29 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
US5834306A (en) * 1994-12-23 1998-11-10 Sri International Tissue specific hypoxia regulated therapeutic constructs
AU3593200A (en) * 1999-02-09 2000-08-29 Powderject Vaccines, Inc. (mycobacterium tuberculosis), immunization
EP1523331B1 (fr) * 2002-07-13 2013-02-27 Statens Serum Institut Vaccin therapeutique contre la tuberculose
WO2005037222A2 (fr) * 2003-10-16 2005-04-28 The Regents Of The University Of California Compositions immunogenes de pathogenes intracellulaires recombinants et procedes d'utilisation de celles-ci
US20070275002A1 (en) * 2003-12-02 2007-11-29 Van Der Werf Sylvie Use Of Proteins And Peptides Encoded By The Genome Of A Novel Sars-Associated Coronavirus Strain

Also Published As

Publication number Publication date
DE602007013248D1 (de) 2011-04-28
EP1882741B1 (fr) 2010-06-30
WO2008012693A3 (fr) 2008-04-24
WO2008012693A2 (fr) 2008-01-31
ATE472602T1 (de) 2010-07-15
DE602006015180D1 (de) 2010-08-12
ATE502110T1 (de) 2011-04-15
EP2049667B1 (fr) 2011-03-16
US20090304637A1 (en) 2009-12-10
US20120156169A1 (en) 2012-06-21
ES2347812T3 (es) 2010-11-04
DK1882741T3 (da) 2010-10-11
JP2009544305A (ja) 2009-12-17
EP2049667A2 (fr) 2009-04-22
EP1882741A1 (fr) 2008-01-30
CA2658713A1 (fr) 2008-01-31

Similar Documents

Publication Publication Date Title
MX2015005252A (es) Metodo novedoso para tratar infarto cardiaco utilizando fragmento de hmgb1.
MX2010006823A (es) Metodos para el tratamiento de la gota.
NZ725347A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
HK1112753A1 (en) Recombinant mycobacterium strain expressing a mycobacterial fap protein under the control of a promoter active under hypoxia and its application for cancer therapy
EP2542582A4 (fr) Protéines thérapeutiques de liaison à dll4
WO2007146425A3 (fr) Composés et procédés destinés au traitement prophylactique d'une anémie induite par une chimiothérapie
UA87627C2 (ru) Фармацевтическая композиция в виде тестостеронового геля и ее использование при лечении гипогонадизма у мужчин
MX2016003943A (es) Composiciones y formulaciones para la prevencion y reduccion de tumorigenesis, invasion y proliferacion de celulas de cancer y metodos de produccion y uso en el tratamiento del cancer.
IN2014CN04401A (fr)
UA117096C2 (uk) Поліпептид, що зв'язується з c5 комплементу людини
SG178930A1 (en) Therapeutic dll4 binding proteins
NO20091661L (no) Anvendelse av pegylert IL-10 for a behandle kreft
WO2010045388A3 (fr) Utilisation des protéines de liaison aux mmp-9 et mmp-12 dans le traitement et la prévention de la sclérose systémique
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
WO2011159685A3 (fr) Inhibition de l'interaction de la protéine wdr5 avec ses partenaires de liaison et méthodes thérapeutiques associées
WO2009105585A3 (fr) Agents de chimiodénervation ciblés de manière postsynaptique et leurs procédés d’utilisation
AP3277A (en) Gene encoding human glucokinase mutant, enzyme encoded by the same, recombinant vectors and hosts, pharmaceutical compositions and uses thereof, methods for treating and preventing diseases
MX365899B (es) Composición farmacéutica que comprende un fragmento de péptido de hmgb1 para usarse en tratamiento de daño a la medula espinal.
MX364623B (es) Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
EP4013431A4 (fr) Polythérapie avec transgènes contrôlés par l'or
NZ721015A (en) Mutant fragments of ospa and methods and uses relating thereto
WO2009123950A3 (fr) Chimère comprenant une cytotoxine bactérienne et procédés d’utilisation de celle-ci
MX358785B (es) Hemoglobina pegilada reticulada con diaspirina.
WO2008148932A3 (fr) Procédé pour le traitement de cancers ou de maladies inflammatoires
MX2021012872A (es) Polipeptidos multiespecificos terapeuticos activados mediante intercambio de cadenas polipeptidicas.